PL1684715T3 - Kompozycje zawierające nerameksan - Google Patents

Kompozycje zawierające nerameksan

Info

Publication number
PL1684715T3
PL1684715T3 PL04810445T PL04810445T PL1684715T3 PL 1684715 T3 PL1684715 T3 PL 1684715T3 PL 04810445 T PL04810445 T PL 04810445T PL 04810445 T PL04810445 T PL 04810445T PL 1684715 T3 PL1684715 T3 PL 1684715T3
Authority
PL
Poland
Prior art keywords
neramexane
compositions
Prior art date
Application number
PL04810445T
Other languages
English (en)
Inventor
Mahendra G Dedhiya
Shashank Mahashabde
Yan Yang
Anshu Goel
Erhard Seiller
Bernhard Hauptmeier
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1684715(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of PL1684715T3 publication Critical patent/PL1684715T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04810445T 2003-11-05 2004-11-05 Kompozycje zawierające nerameksan PL1684715T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51798103P 2003-11-05 2003-11-05
PCT/US2004/037026 WO2005044228A2 (en) 2003-11-05 2004-11-05 Compositions comprising cyclohexylamines and aminoadamantanes
EP04810445A EP1684715B1 (en) 2003-11-05 2004-11-05 Compositions comprising neramexane

Publications (1)

Publication Number Publication Date
PL1684715T3 true PL1684715T3 (pl) 2011-09-30

Family

ID=34572981

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04810445T PL1684715T3 (pl) 2003-11-05 2004-11-05 Kompozycje zawierające nerameksan

Country Status (19)

Country Link
US (4) US20070270500A1 (pl)
EP (2) EP2289489B1 (pl)
AR (1) AR046314A1 (pl)
AT (1) ATE504290T1 (pl)
AU (1) AU2004287489B9 (pl)
CA (1) CA2543865C (pl)
CL (1) CL2008000125A1 (pl)
CY (1) CY1111456T1 (pl)
DE (1) DE602004032164D1 (pl)
DK (1) DK1684715T3 (pl)
ES (2) ES2362581T3 (pl)
HR (1) HRP20110482T1 (pl)
IL (1) IL175623A (pl)
PL (1) PL1684715T3 (pl)
PT (1) PT1684715E (pl)
SI (1) SI1684715T1 (pl)
TW (1) TWI350750B (pl)
WO (1) WO2005044228A2 (pl)
ZA (1) ZA200603561B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096194A2 (en) * 2004-06-17 2006-09-14 Merz Pharma Gmbh & Co. Kgaa Drinkable immediate release tablet made with direct compression of memantine or neramexane
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20070060887A1 (en) * 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector
TW200916091A (en) * 2007-06-08 2009-04-16 Merz Pharma Gmbh & Amp Co Kgaa Neramexane for the treatment of nystagmus
MX2010002733A (es) 2007-09-12 2010-04-09 Merz Pharma Gmbh & Co Kgaa Terapia de intervalo para el tratamiento de tinnitus.
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CN102858321A (zh) 2010-06-18 2013-01-02 莫茨药物股份两合公司 用于局部使用1-氨基-烷基环己烷衍生物的凝胶制剂
US10610502B1 (en) * 2019-08-30 2020-04-07 Metacel Pharmaceuticals, LLC Oral baclofen solutions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
DE69229598T2 (de) 1991-04-19 1999-11-04 Children's Medical Center Corp., Boston Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
WO1999001416A2 (en) 1997-06-30 1999-01-14 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders

Also Published As

Publication number Publication date
CY1111456T1 (el) 2015-08-05
TWI350750B (en) 2011-10-21
AU2004287489B9 (en) 2008-10-09
EP2289489A3 (en) 2012-06-06
CA2543865C (en) 2012-09-04
AU2004287489A1 (en) 2005-05-19
AR046314A1 (es) 2005-11-30
EP2289489A2 (en) 2011-03-02
US20070270500A1 (en) 2007-11-22
ZA200603561B (en) 2007-07-25
PT1684715E (pt) 2011-05-02
US20120238631A1 (en) 2012-09-20
SI1684715T1 (sl) 2011-07-29
IL175623A (en) 2012-10-31
EP2289489B1 (en) 2014-07-16
DK1684715T3 (da) 2011-07-11
US20100035995A1 (en) 2010-02-11
ES2507500T3 (es) 2014-10-15
WO2005044228A3 (en) 2006-06-22
AU2004287489B2 (en) 2008-08-28
ES2362581T3 (es) 2011-07-07
EP1684715A2 (en) 2006-08-02
HRP20110482T1 (hr) 2011-07-31
DE602004032164D1 (de) 2011-05-19
CL2008000125A1 (es) 2008-03-14
TW200526195A (en) 2005-08-16
WO2005044228A2 (en) 2005-05-19
CA2543865A1 (en) 2005-05-19
EP1684715B1 (en) 2011-04-06
US20140350114A1 (en) 2014-11-27
ATE504290T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
GB0301554D0 (en) Immunostimulatory compositions
GB0305941D0 (en) Composition
GB0319874D0 (en) Novel formulation
GB0302738D0 (en) Composition
GB0318448D0 (en) Formulation
GB0329907D0 (en) Compositions
EP1613352A4 (en) MICRO-AGREED COMPOSITIONS
PT1684715E (pt) Composi??es compreendendo ciclo-hexilaminas e aminoadamantanos
GB0312195D0 (en) Formulation
GB0329597D0 (en) Compositions
GB0320522D0 (en) Formulation
GB0300602D0 (en) Compositions
GB0309317D0 (en) Composition
GB0324574D0 (en) Novel compositions
GB0303876D0 (en) Formulation
GB0328023D0 (en) Novel compositions
GB0316857D0 (en) Compositions
GB0306312D0 (en) Composition
GB0301869D0 (en) Composition
GB0311465D0 (en) Composition
GB0321725D0 (en) Anti-vaginitis compositions
GB0326075D0 (en) Compositions
GB0310479D0 (en) Compositions
GB0310480D0 (en) Compositions
GB0325537D0 (en) Compositions